Introducing the New CE-Marked OncoMate™ MSI Dx Analysis System
A PCR-based fragment-sizing test, the OncoMate™ MSI Dx Analysis System encompasses a complete workflow, from DNA extraction to data analysis, offering an easy-to-use, standardized system. The system targets five mononucleotide-repeat markers (BAT-25, BAT-26, NR-21, NR-24 and MONO-27) that were selected for high sensitivity and specificity to alterations in repeat lengths in samples containing mismatch repair defects [1, 2]. For sample authentication of matched tumor and normal samples, the system uses two pentanucleotide repeat markers (Penta C and Penta D) that were selected for their high level of polymorphism and lower degree of MSI.
The improved system is designed for use as a clinical diagnostic tool for determining a tumor’s MSI status. Knowing MSI status can provide physicians with a functional, molecular measurement of the level of DNA mismatch repair deficiency demonstrated within their patient’s tumor. The OncoMate™ MSI Dx Analysis System offers actionable results that can help guide potential immunotherapy decisions and assist in diagnosing hereditary cancer syndromes, like Lynch Syndrome.
 Bacher, J. et al. (2004) Dis. Markers 20, 237.
 Luchini C., et al. (2019) Annals of Oncology. 30, 1232.